Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety

Caplacizumab is a medicine that has been developed to treat acquired thrombotic thrombocytopenic purpura (TTP). TTP causes serious symptoms. such as thrombocytopenia, a condition in which a patient doesn’t have enough platelets. A recent Phase I study observed both Caucasian and Japanese participants, and found that the treatment did not show adverse effects in either group.

Read the original article on Globe Newswire here.


Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email